Glucosephosphate Dehydrogenase Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Glucosephosphate Dehydrogenase Deficiency. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Glucosephosphate Dehydrogenase Deficiency receives a directional strategic score of 70/100, combining unmet need (86/100), competitive intensity (65/100, where higher means more competition) and market attractiveness (77/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A disease-producing enzyme deficiency subject to many variants, some of which cause a deficiency of GLUCOSE-6-PHOSPHATE DEHYDROGENASE activity in erythrocytes, leading to hemolytic anemia.

The reproducible entity is Patsnap disease ID 7132bef5e608456bb8f63f0628b43dcd with MeSH identifier D005955. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

g p g y g p y y FPG indicates fasting plasma glucose; GBD, Global Burden of Diseases, Injuries, and Risk Factors; PAF, population attributable fraction; and UI, uncertainty interval. Source: Data courtesy of the GBD Study. Institute for Health Metrics and Evaluation. Used with permission. All rights reserved.223 Table 10-3. Global Prevalence and Mortality of Diabetes, 2021 These estimates reflect improvements in demography and population estimation, statistical and geospatial modeling methods, and the addition of nearly 3000 new data sources since the 2024 Statistics Update. During each annual GBD Study cycle, population health estimates are produced for the full time series. Improvements in statistical and geospatial modeling methods and the addition of new data sources may lead to changes in past results across GBD Study cycles. GBD i di Gl b l B d f Di I j i d Ri k F d UI i i l g p g y GBD indicates Global Burden of Diseases, Injuries, and Risk Factors; and UI, uncertainty interval. , j , ; , y Source: Data courtesy of the GBD Study. Institute for Health Metrics and Evaluation. Used with permission. All rights reserved.223 Chart 10-1. Age-adjusted prevalence of diagnosed diabetes in US adults ≥20 years of age, by race and ethnicity and sex (NHANES 2021–2023). This chart shows that between 2021 and 2023 in the United States, the prevalence of diagnosed diabetes was highest for non-Hispanic Black male and female adults followed by Hispanic female and male adults. NH indicates non-Hispanic; and NHANES, National Health and Nutrition Examination Survey. y Source: Unpublished

Review the epidemiology source

Epidemiology evidence 2: Heart Disease and Stroke Statistics—2023 Update Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

9. DIABETES ICD-9 250; ICD-10 E10 to E11. See Tables 9-1 and 9-2 and Charts 9-1 through 9-10 Click here to return to the Table of Contents Click here to return to the Abbreviations Diabetes is a heterogeneous mix of health conditions characterized by glucose dysregulation. In the United States, the most common forms are type 2 diabetes, which affects 90% to 95% of those with diabetes, and type 1 diabetes, which constitutes 5% to 10% of cases of diabetes.1 For this chapter, diabetes type (ie, type 1 diabetes or type 2 diabetes) is used when re- ported as such in the original data source; otherwise, the broader term diabetes is used and may include different diabetes types, of which the vast majority will be type 2 diabetes. Diabetes is defined on the basis of FPG ≥126 mg/dL, 2-hour postchallenge glucose ≥200 mg/dL during an oral glucose tolerance test, random glucose ≥200 mg/dL with presentation of hy- perglycemia symptoms, or HbA1c ≥6.5%2 and may be classified as diagnosed by a health care professional or undiagnosed (ie, meeting glucose or HbA1c crite- rion but without a clinical diagnosis). Prediabetes in- creases the risk of diabetes and is defined as an FPG of 100 to 125 mg/dL, 2-hour postchallenge glucose of 140 to 199 mg/dL during an oral glucose tolerance test, or HbA1c of 5.7% to 6.4%. Diabetes is a ma- jor risk factor for CVD, including CHD, HF, PAD, and stroke.3 The AHA has identified untreated FPG levels of <100 mg/dL for children and adults as 1 of the 7 components of ideal CVH.4 Prevalence Youth • In 2019, 283 000 children and adolescents <20 years of age, or 3

Review the epidemiology source

Epidemiology evidence 3: Heart Disease and Stroke Statistics—2025 Update 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

9. DIABETES ICD-9 250; ICD-10 E10 to E11. See Tables 9-1 through 9-3 and Charts 9-1 through 9-9 Click here to return to the Table of Contents Click here to return to the Abbreviations Diabetes is a heterogeneous condition characterized by glucose dysregulation. In the United States, the most common forms are type 2 diabetes, which affects 90% to 95% of those with diabetes, and type 1 diabetes, which constitutes 5% to 10% of cases of diabetes.1 For this chapter, diabetes type (ie, type 1 diabetes or type 2 diabetes) is used when reported as such in the original data source; otherwise, the broader term diabe- tes is used and may include different diabetes types, of which the vast majority will be type 2 diabetes. Diabe- tes is defined on the basis of FPG ≥126 mg/dL, 2-hour postchallenge glucose ≥200 mg/dL during an oral glu- cose tolerance test, random glucose ≥200 mg/dL with presentation of hyperglycemia symptoms, or HbA1c ≥6.5%2 and may be classified as diagnosed by a health care professional or undiagnosed (ie, meeting glucose or HbA1c criterion but without a clinical diagnosis). Pre- diabetes increases the risk of diabetes and is defined as an FPG of 100 to 125 mg/dL, 2-hour postchallenge glucose of 140 to 199 mg/dL during an oral glucose tolerance test, or HbA1c of 5.7% to 6.4%. Diabetes is a major risk factor for CVD, including CHD, HF, PAD, and stroke.3 The AHA has identified untreated FPG levels of <100 mg/dL for children and adults as 1 of the 8 components of ideal CVH.4 Prevalence Youth • In 2021, 352 000 children and adolescents <20 years of age, or 35 per 10 000 U

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Glucosephosphate Dehydrogenase Deficiency, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Glucosephosphate Dehydrogenase Deficiency thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor is PTH1R. It is a pathway hypothesis, not a claim that every Glucosephosphate Dehydrogenase Deficiency patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 57 registered studies. Recent sampled records include:

• NCT07612345 — High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study (G6PDA PKD); Not yet recruiting; Phase 1; sponsor University of Utah; enrollment 3.
• NCT07522606 — Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study; No longer available; Not Applicable; sponsor BIAL-Portela & Cia SA; enrollment not stated.
• ChiCTR2600120462 — Research on the Application of Large Language Models Based on RAG and FT in the Diagnosis of Pediatric Hematological Diseases; Recruiting; Not Applicable; sponsor Hunan Provincial People's Hospital; enrollment 150.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate PTH1R relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Glucosephosphate Dehydrogenase Deficiency merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if PTH1R modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Glucosephosphate Dehydrogenase Deficiency is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.